Isotechnika Pharma Inc IPHAF

Strategic Transactions Part 3

[Georgealphabeta]

ISA board of directors includes strange additions. 1) A legal advisor to 3SBio specializing in biotech and pharma inc.strategical alliances, transactions and specializing in intelectual property issues - Donald W. Wyatt. 2) Dr Peter Wijngaard of Vifor (part of Galenica Group), formerly director in chargeof global aliances for Roche.  The thing is that ISA didn't let ILJIN to increase ownership in the company in spite of the fact that the increase would come at the cost to ILJIN at approx. double cost per share comparing to present market cost of share. I find these facts very strange, however very encouraging to present shareholders. Coupling all of that with the fact that voclosporin efficacy is the same as competition,but safety profile of voclosporin is superior to its competitors, I think that shareholders are in very good position to profit (or in some cases to decrease their losses) from present situation.Disclosure, I am long on ISA and in next few days I may initiate bigger position in ISA.

[narcissist]

Georgealphabeta - I'm not sure we can conclude anything specific from your analysis. I appreciate the information and agree that those board members have impressive profiles. But the only sure thing we can say is that ISA is represented by directors with intriguing credentials. But I am more interested in the level of comittment each of these Directors have. How many other boards do these

[Georgealphabeta]

By all means ISA is a speculation. When these strange birds with "intriguing credentials" appeared on the BOD, surely ISA got back my attention. Personally, I don't think that these directors are commited to ISA, I think,they are on the board to serve their own respective companies. Well, ISA is priced cheap in the relationship to the future potential profits from this generic